OppenheimerFunds’s Charles River Laboratories CRL Stock Holding History

OppenheimerFunds’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$585K	Sell	4,026 -3,163	-44%	-$416K	﹤0.01%	1304
2018 Q4	$814K	Buy	7,189 +2,761	+62%	+$346K	﹤0.01%	1139
2018 Q3	$596K	Sell	4,428 -533	-11%	-$65.8K	﹤0.01%	1365
2018 Q2	$557K	Sell	4,961 -262	-5%	-$28.3K	﹤0.01%	1378
2018 Q1	$558K	Buy	5,223 +250	+5%	+$26.9K	﹤0.01%	1356
2017 Q4	$544K	Sell	4,973 -152,831	-97%	-$16.6M	﹤0.01%	1468
2017 Q3	$17M	Buy	157,804 +152,875	+3,102%	+$15.7M	0.02%	629
2017 Q2	$499K	Buy	4,929 +216	+5%	+$19.9K	﹤0.01%	1503
2017 Q1	$424K	Buy	4,713 +394	+9%	+$33.5K	﹤0.01%	1561
2016 Q4	$329K	Sell	4,319 -532,540	-99%	-$40.4M	﹤0.01%	1567
2016 Q3	$44.7M	Buy	536,859 +457,265	+574%	+$38.3M	0.06%	356
2016 Q2	$6.56M	Buy	+79,594	New	+$6.56M	0.01%	775
2016 Q1	–	Sell	-2,790	Closed	-$224K	–	1698
2015 Q4	$224K	Buy	+2,790	New	+$201K	﹤0.01%	1621

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

OppenheimerFunds's CRL Position: Q1 2019 in Review

OppenheimerFunds reduced its Charles River Laboratories (CRL) stake by 44% in Q1 2019, selling an estimated $416K and leaving 4,026 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

OppenheimerFunds first reported a position in CRL in Q4 2015 and has held it in 13 quarters since. The position peaked at $44.7M in Q3 2016. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

OppenheimerFunds held 4,026 shares of Charles River Laboratories worth $585K as of Q1 2019.
OppenheimerFunds sold 3,163 Charles River Laboratories shares in Q1 2019, an estimated $416K.
Charles River Laboratories made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1304 holding.
OppenheimerFunds first reported a position in Charles River Laboratories in Q4 2015 and has held it in 13 quarters since.
OppenheimerFunds's Charles River Laboratories position peaked at $44.7M in Q3 2016.
409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.